SuperworthAmphastar Pharmaceuticals EPS AMPH
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- $1.70
- Latest quarter, Q2 FY26
- $0.67
- +5% on a year earlier
- Fiscal year 2025
- $2.04
- −33% on the year before
Amphastar Pharmaceuticals' earnings per share was $1.70 over the twelve months to Jun 30, 2026, down 36% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.67, up 5% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 133% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.04 | −33% |
| FY2024 | $3.06 | +19% |
| FY2023 | $2.58 | +47% |
| FY2022 | $1.76 | +42% |
| FY2021 | $1.24 | +4033% |
| FY2020 | $0.03 | −97% |
| FY2019 | $0.99 | n/a |
| FY2018 | −$0.12 | −233% |
| FY2017 | $0.09 | −59% |
| FY2016 | $0.22 | n/a |
| FY2015 | −$0.07 | n/a |
| FY2014 | −$0.25 | −181% |
| FY2013 | $0.31 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.67 | +5% | $1.70 | |
| Q1 FY26 | $0.14 | −73% | $1.67 | |
| Q4 FY25 | $0.52 | −30% | $2.04 | |
| Q3 FY25 | $0.37 | −53% | $2.26 | |
| Q2 FY25 | $0.64 | −12% | $2.67 | |
| Q1 FY25 | $0.51 | −37% | $2.76 | |
| Q4 FY24 | $0.74 | +9% | $3.06 | |
| Q3 FY24 | $0.78 | −14% | $3.00 | |
| Q2 FY24 | $0.73 | +49% | $3.13 | |
| Q1 FY24 | $0.81 | +62% | $2.89 | |
| Q4 FY23 | $0.68 | +3% | $2.58 | |
| Q3 FY23 | $0.91 | +203% | $2.56 |
Against its peers
Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| ABUSArbutus Biopharma | $0.78 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| Peer median | $1.38 |
Where Amphastar Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Amphastar Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.